On 14 September, we at Open Pharma held our first public event for 3 years – the symposium ‘Who can we trust? Open science and pharma research’. The symposium was a satellite event to the Association of Learned and Professional Society Publishers (ALPSP) Annual Conference and Awards 2022.
Watch this YouTube video for an exciting discussion about the role of open science in building trust in pharma research, with a particular focus on open access and accessible summaries.
Chaired by Richard Smith, former Editor of the BMJ and Chief Executive of the BMJ group, the symposium attracted a varied group of people who don’t often get a chance to meet, including publishers, patients and pharma professionals. Pointed questions were asked, thorny issues discussed, relationships begun, and the conversation felt fresh, lively, and fun.
Tune in to hear from Richard and from an excellent group of speakers:
- Richard Stephens, patient advocate and Co-Editor-in-Chief of Research Involvement and Engagement, who discussed the importance of open access to patients.
- Chris Rains, Vice President of Global Medical Affairs for the Global Portfolio at Takeda, who outlined Takeda’s commitment to publishing their research open access.
- Leila Moore, Director of Open Access Policy at Wiley, who gave a publisher’s perspective on the role and value of open access publishing in communicating pharma research.
- Adeline Rosenberg, Senior Medical Writer at Oxford PharmaGenesis, who discussed target audiences and usage of plain language summaries (PLS).
- Sarah Thomas, Global Medical Publications and Senior Communications Manager at Ipsen, who highlighted Ipsen’s commitment to using PLS to help communicate their research to broader audiences.
- Caroline Halford, Development Director in Medical Education at Springer Healthcare, who discussed the use of accessible summaries at Springer Nature.
